The Biospecimen Management Consortium (BMC) was born out of a critical need identified in the Fall of 2023. Through extensive discussions with diverse stakeholders across the clinical ecosystem, it became evident that organizations of all sizes and locations were grappling with similar challenges in biospecimen management. Despite widespread frustrations, there was a glaring absence of best practices, standardization, and quantifiable data to define the problem.

Recognizing that the current approach to biospecimen management was unsustainable and that patients deserved better, industry leaders rallied behind the idea of collective action. In June 2024, Slope spearheaded the launch of the BMC with eight founding sponsor organizations.

The consortium's mission was clear: to provide a platform for cross-stakeholder collaboration and to drive meaningful change that no single entity could achieve alone.

Today, the BMC has transitioned to a stand-alone non-profit organization with the purpose of raising awareness of the importance and the opportunities of biospecimen management, developing responsible standards and best practices, and advocating for change within the clinical trial ecosystem through efficiencies, policy, and thought leadership.